The majority of chronic phase chronic myeloid leukemia (CML) patients treated with the tyrosine kinase inhibitor (TKI) imatinib mesylate maintain durable responses to the drug. However, most patients relapse after withdrawal of imatinib and advanced stage patients often develop drug resistance. As CML is considered a hematopoietic stem cell cancer, it has been postulated that inherent protective mechanisms lead to relapse in patients. The ATP binding-cassette transporters ABCB1 (MDR-1; P-glycoprotein) and ABCG2 are highly expressed on primitive hematopoietic stem cells (HSCs) and have been shown to interact with TKIs. Herein we demonstrate a dosedependent, reversible inhibition of ABCG2-mediated Hoechst 33342 dye efflux in primary human and murine HSC by both imatinib and nilotinib (AMN107), a novel aminopyrimidine inhibitor of BCR-ABL. ABCG2-transduced K562 cells were protected from imatinib and nilotinib-mediated cell death and from downregulation of P-CRKL. Moreover, photoaffinity labeling revealed interaction of both TKIs with ABCG2 at the substrate binding sites as they compete with the binding of [ 125 I] IAAP and also stimulate the transporter's ATPase activity. Therefore, our evidence suggests for the role of ABC transporters in resistance to TKI on primitive HSCs and CML stem cells and provides a rationale how TKI resistance can be overcome in vivo.
Introduction
The tyrosine kinase inhibitor (TKI) imatinib mesylate is a potent therapeutic agent used in the treatment of chronic myeloid leukemia (CML) owing to its specific inhibition of BCR-ABL kinase activity. 1 Imatinib mesylate has been reported to induce major cytogenetic responses in 60-87% of patients in chronic phase myeloid leukemia, 2,3 but does not seem to deplete stem cells. 4 It can induce long-term remission in chronic phase leukemia 5 and can even be of benefit in accelerated phase and blast crisis. 6 However, upon withdrawal of imatinib therapy, most patients with CML relapse quickly, 4, 7 and advanced stage patients frequently develop resistance to imatinib while receiving treatment. 8 Additionally, BCR-ABL-positive malignant cell clones have been shown to persist within the CD34 þ stem cell fraction even in CML patients where imatinib has induced a complete cytogenetic remission. 9 Several potential mechanisms have been postulated to explain the imatinib resistance observed in CML patients. In some cases, resistance has been linked to amplification of the BCR-ABL gene or to the presence of point mutations in the kinase domain of BCR-ABL. 10, 11 These mutations are sometimes present in the patient's leukemic cells before imatinib therapy. 12 Upregulation of BCR-ABL at the mRNA level as well as an increase in BCR-ABL tyrosine kinase activity in CML stem cells has been reported recently. 13 Moreover, resistance mechanisms independent of BCR-ABL have recently been proposed, such as the relative quiescence of CML stem cells 14 or expression of transporters that could potentially mediate uptake or extrusion of TKI. [15] [16] [17] [18] To overcome acquired resistance mechanisms to imatinib, second-generation BCR-ABL inhibitors have been developed. Nilotinib is a novel aminopyrimidine ATP-competitive inhibitor of BCR-ABL that is more potent and selective compared to imatinib at inhibiting the BCR-ABL tyrosine kinase and thus more readily inhibits proliferation of cells that express BCR-ABL. 19, 20 In addition, nilotinib was found to be effective against many imatinib-resistant cells harboring mutations in BCR-ABL. [21] [22] [23] Given that the leukemia initiating cell in CML leukemia arises from a multipotent HSC, 24 and that normal human hematopoietic stem cells (HSCs) are known to express high levels of the ATP-binding cassette transporter ABCG2, 25, 26 overexpression of ABCG2 may confer drug resistance to the CML stem cell fraction. 13 The characteristic side population (SP) observed by flow cytometry in human and murine HSCs after incubation with Hoechst 33342 27 is due to ABCG2-mediated transport in mouse and man. 25, 26 ABCG2 expression in HSCs has been shown to protect HSCs from cytotoxic agents. 28 Imatinib has been shown to be both a substrate and inhibitor of ABCG2, 17, 18, 29 although some controversy exists over whether or not it can confer resistance in cell line models. 16 To resolve the current controversy whether or not imatinib is an ABCG2 substrate, and as few data are available with regard to mechanisms of resistance to nilotinib, we sought to characterize the interactions of imatinib and nilotinib with ABCG2 expressed in the primitive HSC compartment. We demonstrate interaction of these TKIs with ABCG2 at the substrate binding site.
Materials and methods

Chemicals
Hoechst 33342 and rhodamine 123, were purchased from Sigma Chemical Co. (St Louis, MO, USA). Mitoxantrone was obtained from Wyeth-Pharma GmbH (Mü nster, Germany). Imatinib and nilotinib (AMN107) were from Novartis (Basel, Switzerland). Fumitremorgin C (FTC) was synthesized by Thomas McCloud, Developmental Therapeutics Program, Natural Products Extraction Laboratory, National Institutes of Health (Bethesda, MD, USA).
Cell culture
The CML cell line K562 (DSMZ; German National Resource Center for Biological Material) and K562 cells stably overexpressing ABCG2 30 (a kind gift of Yoshikazu Sugimoto, Department of Chemotherapy, Kyoritsu University of Pharmacy, Tokyo, Japan) were maintained in RPMI (Rosewell Park Memorial Institute) 1640 supplemented with 10% FCS, penicillin and streptomycin. All cells were grown at 371C in a 5% CO 2 atmosphere and maintained in log phase. Cell numbers were determined by hemocytometer and cell viability was assessed by trypan blue exclusion.
Hoechst and antibody staining for flow cytometry analysis
Analysis for human and murine SP cells was essentially performed according to Goodell et al., 27 except that Hoechst was used at 2.5 mg/ml to provide for less stringent efflux conditions. For studies using murine BM, adult hematopoietic cells were obtained from 6-to 8-week-old C57BL/6 mice. Each bone marrow cavity was flushed with HBSS, without calcium or magnesium but supplemented with 2% heat-inactivated calf serum (HBSS þ ). After red cell lysis with 0.01 M NH 4 Cl, cells were filtered through nylon screen (BD Falcon, Heidelberg) and resuspended at 1 Â 10 6 cells/ml in 2 ml of prewarmed Dulbecco's modified Eagle's medium (DMEM) containing 2% fetal bovine serum, 10 mM N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid (DMEM þ ) at 371C for 90 min and Hoechst 33342 (Sigma) at 2.5 mg/ml. The effects of imatinib and nilotinib on the SP phenomenon were analyzed by including these drugs during the Hoechst staining at various concentrations ranging from 20 to 10 mM. To compare the effect of imatinib and nilotinib to known inhibitors of the SP phenotype, we used verapamil (50 and 150 mM) (Sigma), FTC (10 mM) and reserpine (5 mM) (Sigma). After Hoechst staining, cells were washed twice with HBSS þ and kept on ice for further antibody staining. Cells were first incubated with a panel of unconjugated monoclonal antibodies to lineage markers including CD3 (KT31.1), CD5 (53-7.3), CD8 (53-6.7), B220 (6B2), Gr-1 (8C5) and Ter119 (Ly76). The cells were then washed and resuspended in anti-rat IgG F(ab)2 fragment conjugated to phycoerythrin (PE) (Caltag). Cells were subsequently stained with directly conjugated antibodies to Sca-1 (E13-161.7-biotin), c-kit (2B8-APCCy7) (eBioscience), Mac-1 (M1/70-PE) and CD4 (GK1.5-PE). Streptavidin-APC was used to visualize Sca-1. After these steps, cells were resuspended in HBSS þ and analyzed on a triple laser instrument (MoFlo, DakoCytomation Inc., Fort Collins, CO, USA) or four laser instrument (LSRII; BD Biosciences) following propidium iodide (PI) staining (2 mg/ml) to exclude dead cells.
For the studies of human bone marrow, following written informed consent as approved by our Local Ethics Committee, fragments from human femura were obtained from patients undergoing hip replacement surgery. Washout studies were performed as outlined in Mogi et al. 31 Murine KSL cells were preincubated for 30 min in 5 mM imatinib or 100 nM nilotinib and subsequently incubated in TKI and Hoechst for 90 min. Parallel samples were similarly incubated in TKI and Hoechst, but cells were then washed twice and placed back in medium with Hoechst for an additional 90 min, yielding the 'wash out' plots. All experiments were performed at least three times and representative data were depicted.
Cytotoxicity assays with imatinib and nilotinib
K562 cells stably transfected with ABCG2 or parental K562 cells were seeded into 96-well plates at 50 000 cells per well with increasing concentration of imatinib and nilotinib. Cells were subsequently stained with PI after 41-43 h and examined by flow cytometry to determine percent viable cells. Significance of differences in viability were calculated by Student's t-test (95% confidence interval).
Measurement of CRKL phosphorylation within ABCG2-transfected K562 cells
For intracellular staining we used 1.0-5 Â 10 5 parental or ABCG2-transfected K562 cells that were fixed at 371C for 10 min using Fix Buffer I (BD Pharmingen, Heidelberg, Germany) and then immediately stored at À801C for future analysis. Cells were then permeabilized on ice for 30 min in 1 ml BD Phosflow Perm Buffer III (BD Pharmingen), washed twice with BD Pharmingen Stain Buffer and resuspended in 100 ml BD Pharmingen Stain Buffer. 2.5 ml anti-P-CRKL antibody (Y207, Cell Signalling Technologies, Beverly, MA, USA) was added and labeling occurred for 30 min at room temperature in the dark. After incubation with the primary antibody, cells were subsequently washed twice with BD Pharmingen Stain Buffer and incubated with 5 ml fluorescein isothiocyanate-labelled goat anti-rabbit IgG secondary antibody (BD Pharmingen). Cells were again washed and resuspended in 500 ml of BD Pharmingen Stain Buffer for FACS analysis on the LSR II flow cytometer (BD Biosciences). Data were analyzed using FlowJo software (Treestar Inc., Oregon, USA).
Measurement of 14C-imatinib or 14C-nilotinib accumulation
Cell suspension (2 ml) containing 1 Â 10 6 cells/ml in DMEM with 2% FCS were exposed to 14 C-imatinib (specific activity 3.301. MBq/mg) or 14 C-nilotinib (specific activity 25 mCi/mg) at the varying concentrations. The cells were prewarmed at 371C and preincubated (with inhibitor when indicated) for 30 min. After a 2 h incubation period (371C) in drug containing medium, the reaction was terminated by removal of the medium. Samples were rinsed twice with 2 ml ice-cold phosphate-buffered saline. Cells were lysed in 0.5 ml of 1 N NaOH, neutralized with 0.5 ml of 1 N HCl, and transferred to scintillation vials. 10 ml of scintillation cocktail was added to each vial, and the total radioactivity was measured by liquid scintillation counting. Each sample was carried out in triplicate and all experiments were repeated at least three times.
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Effect of imatinib and nilotinib on the binding of [ 125 I]IAAP and the ATP hydrolysis mediated by ABCG2
The photoaffinity labeling and efflux assays in addition to the ATPase assay have been proven to be useful assays for identification of substrates of the ABCG2 transporter. 32 Briefly crude membranes from ABCG2-overexpressing MCF7/FLV1000 cells were incubated with the TKI in different concentrations for 10 min at room temperature in 50 mM Tris-HCl (pH 7.5) and 3-6 nM [
125 I]IAAP (2200 Ci/mmol). The mixture was then incubated for additional 5 min under subdued light. Crosslinking was performed for 10 min with a 365 nm UV lamp at room temperature and were further immunoprecipitated with the BXP-21 ABCG2 antibody (Kamiya Biomedical Co., Seattle, WA, USA), followed by autoradiography. For the ATPase assay crude membranes from the ABCG2 expressing HiFive insect cells (100 mg of protein ml) were incubated at 371C with varying concentrations of imatinib and nilotinib in ATPase assay buffer (0.05 mM KCl, 5 mM sodium azide, 2 mM EDTA, 10 mM MgCl 2 , 1 mM DTT and 50 mM TrisMES pH 6.8) for 5 min. The reaction was started by the addition of 5 mM ATP and was terminated by the addition of 0.1 ml of a SDS solution after 20 min as described previously. 32 
Results
Imatinib and nilotinib abrogate ABCG2-mediated Hoechst 33342 transport and SP phenotype in hematopoietic stem cells
Prior in vitro studies with cell lines have reported that imatinib is an inhibitor of ABCG2-mediated drug resistance. 16, 18 To determine if imatinib or nilotinib could inhibit ABCG2-mediated transport we first examined their effects in murine HSCs. In the murine system, HSCs can be isolated to homogeneity using a combination of surface markers, such as c-kit þ /Sca-1 þ /lineage-cells (KSL cells) 28, 33 or dye efflux studies. 27, 34 However, cells isolated as SP cells are not always pure HSCs, much like in the human system. 35 Therefore, we combined surface marker characteristics with Hoechst dye efflux allowing us to study the interaction of imatinib and nilotinib with ABCG2 specifically in the most primitive stem cell subset. Using a slightly lower Hoechst concentration to provide for greater sensitivity, we typically found that 20-30% of cells with the primitive KSL phenotype fall into the SP region. We studied the ability of imatinib and the novel ATP-competitive BCR-ABL inhibitor nilotinib to inhibit Hoechst efflux in KSL cells. As depicted in Figure 1a , imatinib inhibited ABCG2-mediated Hoechst efflux in a dose-dependent manner, with complete inhibition at 0.8 mM. Nilotinib was found to be a more potent inhibitor of ABCG2, with complete inhibition of Hoechst transport at 100-200 nM. Imatinib and nilotinib were as effective as 10 mM FTC and 5 mM reserpine, known ABCG2 inhibitors, whereas 50 mM verapamil prevented Hoechst transport only slightly.
Inhibition of ABCG2-mediated transport by imatinib or nilotinib was found to be rapidly reversed as seen in Figure 1b . Subsequent to TKI wash out, KSL cells were again visible in the SP gate. We next performed identical experiments with human bone marrow. We incubated total human bone marrow mononuclear cells with Hoechst in the presence or absence of varying concentrations of imatinib or nilotinib. Confirming the results in mouse SP cells, 0.8 mM imatinib completely abrogated ABCG2-mediated Hoechst transport, whereas nilotinib was more potent and completely inhibited transport at 100 nM (data not shown).
In summary, our results with human and murine HSCs show nilotinib to be a more potent inhibitor of ABCG2 than Imatinib.
ABCG2-overexpressing K562 cells are resistant to imatinib and nilotinib
Previous work in ABCG2-transfected cells has addressed the interaction between ABCG2 and TKIs. Some groups have reported a predominantly inhibitory effect on ABCG2, 16 whereas others have demonstrated transport of radioactive compounds. 17 Little data are currently available describing the effects of ABCG2 transport on nilotinib efficacy. 36 We therefore asked whether ABCG2 expression could attenuate imatinib-or nilotinib-induced cell death in BCR-ABL-positive K562 cells. Undetectable levels of ABCG2-mediated Hoechst transport were found in K562 parental cells (Figure 2a, left plot) , whereas high levels of transport were found in ABCG2-transduced cells (right plot), confirming high levels of ABCG2 expression and function in these cells. In addition, BCR-ABL gene expression levels were determined by previously published methods 37 and were not found to be different among parental, ABCG2 transduced or FTC-treated K562 cells as determined by quantitative RT-PCR analysis (data not shown).
As shown in Figure 2b , compared to parental K562 cells, ABCG2-overexpressing K562 cells displayed two-to threefold resistance to imatinib-induced apoptosis, especially at concentrations from 0.065 mM to 0.5 mM imatinib, that is within therapeutically relevant concentrations.
38 By 1 mM imatinib, resistance in the ABCG2-overexpressing cells had been overcome. At imatinib concentrations of 0.065, 0.125 and 0.250 mM, the difference in percentage of viable cells for K562 parental and ABCG2-transduced cells was statistically significant, with Po0.05. When experiments with the same concentrations of imatinib were performed in the presence of 10 mM FTC, resistance to imatinib was completely abrogated (Figure 2b) . Although a two-to threefold resistance to nilotinib was also observed in the K562/ABCG2 cells, this only occurred at nanomolar concentrations of nilotinib (Figure 2c ), suggesting that resistance to nilotinib may not be observed at clinically relevant dose levels. The difference in percent viable cells for K562 parental-and ABCG2-transduced cells was statistically significant (Po0.05) at nilotinib concentrations of 10 and 25 nM.
These experiments demonstrated that ABCG2-transduced K562 cells are resistant to imatinib-and nilotinib-induced cell death and suggested that both TKIs were substrates for ABCG2.
Direct interaction of imatinib and nilotinib with ABCG2 at the substrate binding sites and stimulation of the ABCG2 mediated ATP hydrolysis
We were further interested to disclose the molecular mechanism how both TKIs exert the inhibitory function on the ABCG2 transporter protein. We show that both imatinib and nilotinib inhibit the photolabeling of wild-type ABCG2 with [
125 I]IAAP, indicating that both TKIs directly interact with the transporter at the substrate binding pocket as they compete with the binding of [
125 I]IAAP (Figure 3a) . Consecutively, we also show that both TKIs increase the ATP hydrolytic activity of ABCG2 at low concentrations, (Figure 3b ) which is an indication of their interaction at the drug substrate site of the transporter. 32 Taken together all these approaches clearly prove that imatinib and nilotinib act specifically at the substrate binding site of the ABCG2 transporter protein. The mechanism of TKI AMN107 exhibit high-affinity interaction with ABCG2 C Brendel et al stimulating the ABCG2 ATPase activity and therefore enhancing drug efflux is particularly important in the most primitive hematopoietic stem cell fraction as demonstrated above.
ABCG2 prevents imatinib-and nilotinib-mediated CRKL dephosphorylation in K562 cells
To confirm the results observed in cytotoxicity assays, we next assessed the ability of imatinib and nilotinib to inhibit BCR-ABL- AMN107 exhibit high-affinity interaction with ABCG2 C Brendel et al mediated phosphorylation of the downstream target CRKL in K562 parental and ABCG2-overexpressing K562 cells. We previously demonstrated that flow cytometric measurement of P-CRKL is highly concordant to Western blot analyses. 39 As shown in Figure 4a , untreated K562 parental cells exhibited high levels of P-CRKL, reflecting a high activity of BCR-ABL. Exposure to 500 nM imatinib or 25 nM nilotinib in the parental cell line resulted in a significant loss of CRKL phosphorylation (upper row). In ABCG2-overexpressing K562 cells, only a small fraction of the cells exhibited a decrease of p-CRKL at 500 nM imatinib or 25 nM nilotinib, suggesting intracellular imatinib concentrations were not high enough to dephosphorylate p-CRKL in the same manner (bottom row). This protective effect against p-CRKL dephosphorylation was completely abrogated by the ABCG2 specific inhibitor FTC. Exposure of cells to higher imatinib or nilotinib concentrations (5 mM) resulted in complete dephosphorylation of p-CRKL in both parental and transfected K562 cells (data not shown), consistent with our results in the cytotoxicity assays. These experiments demonstrate that ABCG2 prevents p-CRKL dephosphorylation in a BCR-ABL-dependent cell line.
ABCG2 decreases intracellular accumulation of imatinib and nilotinib
In order to determine if ABCG2-mediated efflux of TKI is responsible for the observed resistance, we incubated ABCG2-overexpressing K562 cells in 200 nM or 1 mM 14 C-imatinib in the presence or absence of FTC and measured intracellular imatinib accumulation. In parental K562 cells, no significant difference in imatinib accumulation was observed in the presence or absence of FTC (Figure 4b ), but in ABCG2-transduced K562 cells, a statistically significant difference in imatinib accumulation was observed in cells incubated with 200 nM imatinib in the presence and absence of FTC. These results are in agreement with previous reports, 13, 16, 17 and suggest that imatinib is transported by ABCG2, but not at high concentrations such as 1 mM. This conclusion is further supported by results obtained when ABCG2-transduced cells were incubated in 200 nM 14 C-imatinib and 800 nM cold imatinib, where no transport was observed. Similarly, a small but statistically significant difference (P ¼ 0.03) in nilotinib accumulation was observed when ABCG2-transduced K562 cells were incubated in 200 nM 14 C-nilotinib in the presence or absence of FTC. Our data support the hypothesis that at least efflux of imatinib owing to ABCG2 transporter activity may be an important resistance mechanism in BCR-ABL-positive stem cells in CML.
Discussion
Although nearly all patients with chronic phase CML achieve an ongoing complete hematologic response after treatment with imatinib, CML cells will reappear after withdrawal of imatinib therapy. 4, 7 Although the nature of this resistance or persistence is not completely defined, second-generation TKIs, such as nilotinib, have been developed to overcome this resistance and have recently been shown to be clinically effective. 40 As CML is a stem cell disease, and stem cells are known to express ABC transporter proteins such as ABCG2 and MDR-1, we sought to characterize the interaction between TKIs and these transporter molecules on primary stem cells. We demonstrate that nilotinib is a more potent ABCG2 inhibitor than imatinib in primitive HSCs. This is consistent with the recently reported results from a phase 1 dose-escalation study of nilotinib in imatinib-resistant CML. 40 Additionally, we show that ABCG2-transduced K562 cells are two-to threefold resistant to imatinib and nilotinib compared to parental cells, and that this resistance is accompanied by persistence of CRKL phosphorylation. Although resistance was found to be within the range of clinically attainable concentrations for imatinib, in the case of nilotinib, resistance was observed only at very low drug concentrations, suggesting that resistance to nilotinib via AMN107 exhibit high-affinity interaction with ABCG2 C Brendel et al ABCG2 may not be observed at clinically relevant levels of nilotinib. 41, 42 The ability of ABCG2 to transport TKIs is viewed as somewhat controversial, partly due to inconsistent methodologies used by different groups. The first report on the interaction of imatinib with ABCG2 was that of Houghton et al., 16 who found imatinib to be an inhibitor, but not a substrate of ABCG2 in Saos-2 cells. In contrast to the report of Houghton et al., 16 Burger et al.
17
demonstrated decreased accumulation of radioactive imatinib after incubating ABCG2-transfected HEK-293 cells in 200 nM imatinib. Jordanides et al. 13 have recently postulated that ABCG2 does not transport imatinib, because they did not observe a difference in imatinib accumulation when CD34 þ CML cells were incubated with 5 mM imatinib in the presence or absence of FTC.
As the evidence seemed to suggest that ABCG2-mediated differences in imatinib accumulation only became apparent when cells were incubated in low imatinib concentrations, we incubated ABCG2-transduced K562 cells in 200 nM or 1 mM 14 C-imatinib in the presence or FTC. We were able to observe an ABCG2-mediated decrease in imatinib accumulation only in cells incubated in 200 nM imatinib, supporting the notion that at 1 mM imatinib, resistance had been overcome. This finding particularly reflects the clinical observation, that resistance can in part be overcome by dose escalation. Using We demonstrate FTC-reversible, ABCG2-mediated resistance to imatinib induced cell death in ABCG2-expressing K562 cells, a finding also recently reported by Nakanishi et al. 43 Taken together imatinib and nilotinib act as ATPase stimulating substrates for ABCG2 with greater affinity than other known ABCG2 substrates. As functional ABCG2 is overexpressed on primary CML stem cells 13 and normal and leukemic stem cells exhibit similar functional gene expression profiles 44 TKI efflux mediated by this transporter implies a resistance mechanism of significant biological and clinical relevance, in particular with regards to the most primitive hematopoietic stem cell fraction.
Imatinib plasma concentrations range between 0.8 and 1.2 mM at trough with 400 mg once-daily administration 45 and considerably lower levels (0.07-0.25 mM at peak) can be found in other body compartments like cerebrospinal fluid. 46 Isolated central nervous system relapses have been reported in 20% of patients with blast crisis CML or BCR-ABL-positive acute lymphoblastic leukemia (ALL) under ongoing imatinib treatment. 47 Therefore, dose escalation or combined treatment regimen 48 appear to be rational therapy strategies for those patients.
Moreover, our data regarding high-affinity interaction of TKI in the most primitive HSC compartment raises concern about long-term safety of these drugs, because healthy HSC are continuously disabled to efflux toxic substrates under ongoing imatinib therapy. Therefore, our data are consistent with the recent clinical observation that continued imatinib treatment can lead to hematopoietic stem cell disorders like MDS and AML. 49 Thus understanding the mechanism how TKIs mitigate ABC transporter function with regard to the most primitive hematopoietic stem cell fraction may lead to prolonged treatment benefits for patients with CML or Philadelphia-chromosome positive ALL. like to thank Hans-Peter Elsässer at the laboratory of Cell Biology, Marburg, for help with the liquid scintillation experiments. We thank Kathleen Stabla and Petra Roth for skilful technical assistance. In addition we appreciate the kind gift from Professor Yoshikazu Sugimoto (Tokyo, Japan) who provided the ABCG2-transfected K562 cell line. We would also like to thank Beverly Torok-Storb for critical reading of this paper.
